M101 the effect of bruton tyrosine kinase inhibitor ibrutinib on diagnostic evaluation amoxicillin allergy

Bruton Tyrosine Kinase (BTK) Inhibitors are used to treat chronic lymphocytic leukemia. BTK is involved in B cell receptor signaling and downstream signaling in mast cell and basophils. The BTK inhibitor Ibrutinib may block mast cell and basophil mediator release and may affect IgE levels.

Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: R. Charya, D. Sheth, A. Aggarwal Source Type: research